InMed Pharmaceuticals

Company snapshot

InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three drug development programs in the treatment of Alzheimer’s, ocular and dermatological indications. Together with our subsidiary BayMedica, we are a global leader in the manufacturing, development and comm

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 15 US patent(s) indexed to this assignee profile.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for InMed Pharmaceuticals. Not investment advice.

• What is InMed Pharmaceuticals?

  InMed Pharmaceuticals is a pharma organization headquartered in Vancouver, CA. It trades on NYSE under ticker INM. Primary therapeutic focus areas include Epidermolysis Bullosa Simplex. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 15 patent record(s) to this

• Is InMed Pharmaceuticals publicly traded?

  Yes. InMed Pharmaceuticals is listed with ticker INM on NYSE per SEC EDGAR records linked on this profile.

• What drugs does InMed Pharmaceuticals develop or market?

  No drug profiles are currently linked to InMed Pharmaceuticals. Pipeline programs may still list investigational assets.

• What are the latest developments for InMed Pharmaceuticals?

  In the last 12 months our linked public records show 1 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does InMed Pharmaceuticals focus on?

  InMed Pharmaceuticals focuses on Epidermolysis Bullosa Simplex based on our analysis of their pipeline programs and drug development activities.